Mobocertinib

105 interactions 10 explained in plain English

Also sold as: Exkivity

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Lefamulin Medroxyprogesterone Clindamycin Topical Metronidazole Topical Oxaliplatin Injection

2 Contraindicated 100 Major 3 Moderate

All (105) Contraindicated (2) Major (100) Moderate (3)

Major

Mobocertinib Docetaxel Injection Beizray Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Dofetilide Tikosyn Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure; QT interval prolongation Details Mobocertinib Dolasetron Anzemet An increased risk of QT interval prolongation Details Mobocertinib Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Mobocertinib Encorafenib Braftovi Reduced mobocertinib exposure, reduced efficacy of mobocertinib and an increased risk of QT interval prolongation Details Mobocertinib Entrectinib Rozlytrek Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure; QT interval prolongation Details Mobocertinib Eribulin Injection Halaven An increased risk of QT interval prolongation Details Mobocertinib Estradiol Delestrogen Reduced exposure of the hormonal contraceptive, which may result in reduced contraceptive efficacy and an increased risk of breakt... Details Mobocertinib Estradiol Topical Divigel Reduced exposure of the hormonal contraceptive, which may result in reduced contraceptive efficacy and an increased risk of breakt... Details Mobocertinib Estradiol Transdermal Patch Alora® Reduced exposure of the hormonal contraceptive, which may result in reduced contraceptive efficacy and an increased risk of breakt... Details Mobocertinib Everolimus Afinitor Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Famotidine Calmicid An increased risk of QT interval prolongation Details Mobocertinib Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Mobocertinib Felbamate Felbatol An increased risk of QT interval prolongation Details Mobocertinib Fentanyl Transdermal Patch Duragesic® Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Flecainide Tambocor® An increased risk of QT interval prolongation Details Mobocertinib Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Mobocertinib Galantamine Razadyne An increased risk of QT interval prolongation Details Mobocertinib Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Mobocertinib Gemifloxacin Factive An increased risk of QT interval prolongation Details Mobocertinib Glasdegib Daurismo An increased risk of QT interval prolongation Details Mobocertinib Goserelin Implant Zoladex An increased risk of QT interval prolongation Details Mobocertinib Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Mobocertinib Granisetron Injection Granisol An increased risk of QT interval prolongation Details Mobocertinib Histrelin Implant Supprelin An increased risk of QT interval prolongation Details Mobocertinib Hydroxychloroquine Plaquenil An increased risk of QT interval prolongation Details Mobocertinib Inotuzumab Ozogamicin Injection Besponsa An increased risk of QT interval prolongation Details Mobocertinib Ivabradine Corlanor An increased risk of QT interval prolongation Details Mobocertinib Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Mobocertinib Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Mobocertinib Lenvatinib Lenvima An increased risk of QT interval prolongation Details Mobocertinib Letermovir Injection Prevymis Increased mobocertinib exposure and increased risk of adverse reactions, including QT-interval prolongation Details Mobocertinib Levofloxacin Levaquin An increased risk of QT interval prolongation Details Mobocertinib Levofloxacin Injection Levaquin An increased risk of QT interval prolongation Details Mobocertinib Levonorgestrel After banger Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Mobocertinib Levonorgestrel Intrauterine System Kyleena Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Mobocertinib Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Mobocertinib Lumateperone Caplyta Reduced lumateperone exposure Details Mobocertinib Medroxyprogesterone Amen® Reduced exposure of the hormonal contraceptive, which may result in reduced contraceptive efficacy and an increased risk of breakt... Details Mobocertinib Medroxyprogesterone Injection Depo-Provera Reduced exposure of the hormonal contraceptive, which may result in reduced contraceptive efficacy and an increased risk of breakt... Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.